Applied Filters
LSIPR 50 2017: Doochul Kim
Doochul Kim was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.
LSIPR 50 2017: Xi Jinping
Xi Jinping was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.
LSIPR 50 2017: Raj Panjabi
Raj Panjabi was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
Aslan: fighting cancer head-on
Based in Singapore, biotech company Aslan Pharmaceuticals specialises in developing new treatments to fight cancers that are prevalent in Asia, often requiring licensing deals to ensure it is fully equipped. LSIPR spoke to general counsel Ben Goodger to find out more.
Life sciences regulation in India: the need for evolution
India’s regulatory environment surrounding pharmaceuticals and medical devices needs to evolve in order to unlock the industries’ true potential, says Kirit Javali of Jafa & Javali.
IP service providers: a more cost-effective solution post M&A?
With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.
Russian patent law: Natural selection
There is some debate among Russian legal professionals about whether “selection inventions” are considered patentable, but the answer seems clear, says Valery Djermakian of Gorodissky & Partners.
Technology transfer: A smart way of working
‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.
Working together wisely
In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.
Boom and boom in the People’s Republic
Over the past few years China’s life sciences sector has become a hive of activity as specialist IP courts have been implemented and M&A activity has ramped up. LSIPR assesses some of these developments.
